


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound having the formula:



wherein

R^9 and R^{10} are members independently selected from H, substituted or unsubstituted alkyl and acyl;

R^3 is H;

R^4 is selected from H, OMe and OH;

R^5 is OR^{14} , wherein R^{14} is a member selected from H and unsubstituted alkyl;


R^6 is OR^{14} , wherein R^{14} is a member selected from H, substituted or unsubstituted alkyl and $\text{P}(\text{O})(\text{OR}^{17})(\text{OR}^{17})$, wherein each R^{17} is independently selected from substituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted phenyl,

wherein a member selected from R^5 and R^3 ; and R^6 and R^3 together with the atoms to which they are attached are optionally joined to form a ring system selected from substituted or unsubstituted heterocycloalkyl; and

R⁸ is unsubstituted alkyl.

2.-7. (Canceled)

8. (Original) The compound according to claim 1, wherein R⁶ has the formula:



in which


R²² is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

Ar is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

9. (Original) The compound according to claim 8, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

10. (Original) The compound according to claim 1, wherein R⁶ has the formula:



in which

R²² is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

n is an integer from 1 to 30.

11. (Original) The compound according to claim 10, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

12. (Original) A formulation of the compound according to claim 1, and a second compound having the formula:

A-B

wherein

A is a hydrophobic domain; and

B is a hydrophilic domain covalently bound to A.

13. (Original) The formulation according to claim 12, further comprising a polycationic species.

14. (Original) The formulation according to claim 13, wherein said polycationic species is a dendrimeric polyamine.

15. (Original) The formulation according to claim 12, wherein said formulation is an aqueous formulation.

16.-28. (Canceled)